Clean Science Q1: consolidated PAT flat +4.7% YoY at ₹73 Cr as operating margins compress

Clean Science posted Q1 FY27 (Jun-26) consolidated revenue of ₹268.4 Cr, up 10.5% YoY (+7.7% QoQ), but net profit rose only 4.7% YoY to ₹73.4 Cr — profit growth trailing topline growth by a wide margin. The gap is the story: operating (EBITDA) margin compressed to ~35.9% from 41.1% a year ago (and 38.4% last quarter), so operating profit actually fell ~3% YoY despite double-digit revenue. The reported PAT held up only because other (treasury) income jumped 65% YoY to ₹22.2 Cr; strip it out and the underlying print is soft. The eye-catching +26% QoQ PAT is almost entirely a non-operating artifact — other income swung from ₹2.8 Cr in Q4 to ₹22.2 Cr this quarter (~₹19 Cr, roughly the entire ₹15 Cr QoQ profit gain), while operating EBITDA was near-flat sequentially.

The result validates management's cautious May-2026 concall tone: they gave no quantitative FY27 guidance, flagging a 'very tricky' macro with China pricing pressure, and this quarter's margin squeeze — sitting on the gross-margin/realisation line (cost of materials consumed rose faster than revenue) — is exactly that pressure showing up. The promised margin relief from captive Hydroquinone/Catechol consumption and Performance Chemical-2 (commercialisation targeted Sep-2026) has not yet arrived; management had itself said the new plant needs another 1-2 quarters to optimise, so margins remain a FY27 wait-and-watch.

The stock went into the print at ₹734.05, down 5.6% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

Standalone PAT ₹73.3 Cr near-identical to consolidated — consolidated revenue higher (₹268 vs ₹207 Cr standalone) via Clean Fino-Chem

Against that, the HALS growth engine kept building strategically even if it didn't rescue this quarter's margins: alongside the result the board flagged the July-16 Clean Fino-Chem–Geneus Chem AG (Switzerland) collaboration for advanced HALS grades on an exclusive basis (with a 25% warrant-linked stake), and a separate 5-year supply deal with Kemin Industries. The board also declared a final dividend, cleared a wholly-owned Netherlands step-down subsidiary, and appointed Krishnakumar Saboo as Whole-time Director. No published brokerage consensus for this specific quarter was found, so the print can't be scored against a street number; on management's own (qualitative) frame, volumes/HALS momentum are intact but the margin-improvement thesis is unmet so far.